Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
Active, not recruiting · NCT04270175 · Registry updated 2026-02-27Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab | Alzheimer disease, Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, brain disorder, central nervous system disorder, cognitive disorder, dementia, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, nervous system disorder, neurodegenerative disease, plasma cell neoplasm, proteostasis deficiencies, psychiatric disorder, tauopathy | Active, not recruiting | Phase 2 | 2026-02-27 | NCT04270175 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Janssen Scientific Affairs, LLC | 37 |
| Weill Medical College of Cornell University | 276 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Boston University Medical Center | Boston | United States | 16 |
| Medical College of Wisconsin | Milwaukee | United States | 483 |
| Stanford University | Palo Alto | United States | 161 |
| Weill Cornell Medicine - Multiple Myeloma Center | New York | United States | 2 |